The aim of this course is to provide participants with an understanding of missing data, its link with what is to be estimated in a study (the “estimand”), and statistical modelling approaches. The 2 day course includes workshops: participants will undertake a number of practical exercises on missing data in SAS.
The course will provide participants the opportunity to gain insight into some of the more useful new methodologies for missing data, with a view to being at the service of the real scientific question of interest. Multiple imputation (MI) will be emphasised – due to this method’s flexibility.
Attendees will require a laptop with access to SAS.
The following topics will be covered:
- History of research into missing data
- Prevention of missing data and impact on study power
- Missing Data and its relation to the estimand
- Estimands and their models
- Multiple imputation I: models for missing data
- Weighting I: weighting for missing data
- Multiple imputation II: methods for non-continuous endpoints
- Weighting II: augmenting weighed data with model estimates
- Composite endpoints
- Case studies
Course runs from:
10:00 - 17:00 (registration from 09:00) on Day 1
09:00 - 16:00 on Day 2
Registration costs include lunch and refreshments. PSI are holding a limited number of hotel rooms until the 31st January 2018 which will be allocated on a first come first served basis.
PSI, the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) and the Biopharmaceutical Section of the American Statistical Association (ASA) are jointly organising a webinar on Estimands in Practice. Speakers from regulatory authorities (FDA and EMA) and industry will present on their experience on this topic to date.
Discover your potential by working as a Covance Senior Principal / Principal Biostatistician. You'll enjoy a varied role working for different sponsors across several therapeutic areas, leading projects and mentoring junior members of the department.
Biometrics at AstraZeneca provides the data that influences decisions on how we roll back the frontiers of science to bring life-changing medicines to the world. We are at the heart of design, analytics and interpretation of AstraZeneca’s portfolio.